Vitamin C Purchasers Awarded $162 Million In First-Ever Civil Price-Fixing Verdict Against Chinese Companies

On March 14, 2013, a federal jury in Brooklyn, New York returned a verdict in In re Vitamin C Antitrust Litigation, No. 1:06-md-1738 (E.D.N.Y.), finding that two Chinese companies had unlawfully fixed prices and controlled the supply of vitamin C exports from China to the United States. The jury rejected the companies’ defense that their actions were compelled by the Chinese government. The jury awarded the plaintiffs $54.1 million, which was trebled by the court to $162.3 million.

The case represents the first time that a Chinese company has been found liable for violating United States antitrust laws. It is equally noteworthy for the Chinese government’s unprecedented appearance in the case in support of the companies’ claim of immunity under the foreign sovereign compulsion doctrine. The verdict sends a strong signal to non-US manufacturers that the application of foreign laws may not be enough to avoid antitrust liability in US courts. Given China’s growing role in global commerce and the economic realities that Chinese companies face domestically, the jury’s verdict in this case is only the first word on whether US courts will accept a Chinese company’s argument that “the government made me do it.”

Please see full publication below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Shearman & Sterling LLP
Contact
more
less

Shearman & Sterling LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide